拉巴胺的使用减缓了心脏移植血管病变的进展
Donna Mancini1, Sean Pinney, Daniel Burkhoff
1Columbia University, New York, NY, USA. dmm31@columbia.edu
Circulation
|May 14, 2003
概括
拉巴胺显著减缓了心脏移植患者心血管病变的进展. 这种免疫抑制药物通过抑制细胞增殖和迁移来减少不良事件,提供了一个新的治疗途径.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 药理学 药理学 是一个学科.
背景情况:
- 心脏移植血管病是心脏移植接受者晚期死亡的主要原因.
- 拉巴素是一种免疫抑制剂,具有抗增殖和抗迁移的特性.
- 这项研究研究了拉帕米辛在预防严重病例的移植血管病变进展方面的疗效.
研究的目的:
- 评估拉巴素对心脏移植后心血管病变的进展的影响.
- 评估拉帕米辛在减轻与移植血管病变相关的不良临床事件方面的潜力.
主要方法:
- 一项随机试验涉及46名患有严重心脏血管病的患者.
- 患者接受了拉巴胺或持续的标准免疫抑制.
- 每年进行心脏导管,监测不良事件,评估抗体产生.
主要成果:
- 与对照组相比,拉巴胺治疗显著降低了初级终点 (死亡,再血管化,心肌梗塞,得分恶化) 的发生率 (3对14名患者,P<0.001).
- 两组之间没有观察到基线特征或抗HLA抗体生产的显著差异.
- 拉帕和对照组的随访时间相似.
结论:
- 拉帕米辛在心脏移植接受者中表现出显著的减缓心血管病变进展的能力.
- 药物的抗增殖和抗迁移作用可能是观察到的好处的原因.
- 拉帕米辛是治疗移植血管病的有前途的治疗策略.
相关概念视频
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...